{
  "ticker": "JNJ",
  "target_date": "2025-06-12",
  "actual_date": "2025-06-12",
  "collected_at": "2025-12-08T11:53:05.554691",
  "price": {
    "open": 154.12,
    "high": 154.56,
    "low": 153.07,
    "close": 154.53729248046875,
    "volume": 7075500,
    "change_1d_pct": 0.9,
    "change_7d_pct": 1.45,
    "change_30d_pct": 1.08
  },
  "technicals": {
    "rsi_14": 69.48,
    "sma_20": 151.25,
    "sma_50": 150.93,
    "macd": 0.759,
    "macd_signal": 0.314,
    "macd_histogram": 0.444,
    "bb_upper": 155.58,
    "bb_lower": 146.93,
    "price_vs_sma20_pct": 2.17,
    "price_vs_sma50_pct": 2.39,
    "volume_ratio": 0.93
  },
  "fundamentals": {
    "market_cap": 489183248384,
    "pe_ratio": 19.598455,
    "forward_pe": 19.154716,
    "price_to_book": 6.162625,
    "price_to_sales": 5.308612,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.3,
    "pct_from_52w_low": 44.33
  },
  "macro": {
    "spy": {
      "price": 600.31,
      "change_1d_pct": 0.4,
      "change_7d_pct": 1.31
    },
    "vix": {
      "level": 18.02,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.36
    },
    "dollar_index": {
      "level": 97.92
    },
    "gold": {
      "price": 3380.9
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia",
      "source": "Yahoo",
      "datetime": 1749740400,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rea",
      "url": "https://finnhub.io/api/news?id=da21608c02f02433d39361603e63297b817388d00bb9ff8a07a8190013907f22"
    },
    {
      "headline": "Impax Global Opportunities Fund Q1 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1749738720,
      "summary": "The fund underperformed the benchmark during the last quarter.",
      "url": "https://finnhub.io/api/news?id=55ef6bc7cae26e7ed6f37f450a70499c47409f0159c8a81d6fd7d66fb953d33b"
    },
    {
      "headline": "New Results for Johnson & Johnson's Bleximenib Demonstrating Antileukemic Activity in Combination with Venetoclax and Azacitidine for Acute Myeloid Leukemia",
      "source": "Finnhub",
      "datetime": 1749737133,
      "summary": "Johnson & Johnson announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib in combination with venetoclax and azacitidine for the treatment...",
      "url": "https://finnhub.io/api/news?id=d9d29fbd00378ad173b0e4c8a5cadd21dd3bbf76c9a6ad79946931bd829a88cb"
    },
    {
      "headline": "Johnson & Johnson : Significant efficacy benefit of IMBRUVICA\u00ae (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia su",
      "source": "Finnhub",
      "datetime": 1749731592,
      "summary": "Media contact: Jenni Mildon jmildon@its.jnj.com +44 7920 418 552 Investor contact: ...",
      "url": "https://finnhub.io/api/news?id=a1bbbff37a96907c468ff3001625fb55cf8b7b3ac456e00456f1ebd48db8bc2c"
    },
    {
      "headline": "Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image",
      "source": "MarketWatch",
      "datetime": 1749729420,
      "summary": "Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image",
      "url": "https://finnhub.io/api/news?id=0b382baa996a937fe2e5e05f64a5a3492e11fa48447180bc5d19353b14653c11"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760229.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000154/xslF345X05/wk-form4_1749760229.xml"
    },
    {
      "form": "8-K",
      "date": "2025-06-10",
      "description": "jnj-20250610.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000152/jnj-20250610.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}